Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
93 hedge funds and large institutions have $452M invested in Aratana Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 12 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 21
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
7% more funds holding
Funds holding: 87 → 93 (+6)
11% less capital invested
Capital invested by funds: $510M → $452M (-$58.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12M |
| 2 |
CCI
Columbus Circle Investors
|
+$10.8M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$3.6M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$12.1M |
| 2 |
JP Morgan Chase
New York
|
-$5.95M |
| 3 |
Goldman Sachs
New York
|
-$5.23M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.73M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$3.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
101
Sterling Capital Management
Charlotte,
North Carolina
| – | -$220K | -12,373 | Closed |
|
|
CIA
102
Capital Impact Advisors
Boston,
Massachusetts
| – | -$184K | -10,331 | Closed |
|
103
Creative Planning
Overland Park,
Kansas
| – | -$27K | -1,500 | Closed |
|
104
Dimensional Fund Advisors
Austin,
Texas
| – | -$18K | -1,000 | Closed |
|
|
GT
105
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$18 | +1 | New |
|
PETX Hedge Fund Activity: Q1 2015 in Review
93 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q1 2015, worth a combined $452M — down 11% from $510M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PETX positions and 12 closed out — a net gain of 6 holders — while 41 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $12M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $12.1M sold.
- 93 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q1 2015, up from 87 in Q4 2014.
- Funds reported $452M of Aratana Therapeutics, Inc. stock for Q1 2015, down 11% quarter-over-quarter.
- 18 funds opened new Aratana Therapeutics, Inc. positions in Q1 2015 and 12 closed out, a net change of +6 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q1 2015 was State Street, an estimated $12M added.
- The largest Aratana Therapeutics, Inc. seller in Q1 2015 was D.E. Shaw & Co, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2015.